troriluzole + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Spinocerebellar Ataxias
Conditions
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10
Trial Timeline
Mar 8, 2019 → Jun 1, 2026
NCT ID
NCT03701399About troriluzole + Placebo
troriluzole + Placebo is a phase 3 stage product being developed by Biohaven for Spinocerebellar Ataxias. The current trial status is active. This product is registered under clinical trial identifier NCT03701399. Target conditions include Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04693351 | Phase 3 | Completed |
| NCT04641143 | Phase 3 | Completed |
| NCT03701399 | Phase 3 | Active |
| NCT03829241 | Phase 3 | Completed |
| NCT03299166 | Phase 2/3 | Completed |
Competing Products
15 competing products in Spinocerebellar Ataxias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373, High dose + KPS-0373, Low dose + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2 | 51 |
| BIIB132 + BIIB132-Matching Placebo | Biogen | Phase 1 | 30 |
| IVIG | Baxter | Phase 2 | 49 |
| Intravenous Immune Globulin (IVIG) | Baxter | Phase 1 | 30 |
| ARO-ATXN2 Injection + Placebo | Arrowhead Pharmaceuticals | Phase 1 | 30 |
| Troriluzole + Placebo + Troriluzole | Biohaven | Phase 2/3 | 60 |
| BHV-4157 | Biohaven | Pre-clinical | 18 |